

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 0 882 450 A2

(12) EUROPEAN PATENT APPLICATION

(43) Date of publication:
09.12.1998 Bulletin 1998/50

(51) Int. Cl.⁶: A61K 31/12, A61K 31/05

(21) Application number: 98401263.3

(22) Date of filing: 27.05.1998

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(72) Inventors:
• Mae, Tatsumasa
Kakogawa-shi, Hyogo 675-0102 (JP)
• Hidaka, Takayoshi
Kobe-shi, Hyogo 655-6006 (JP)

(30) Priority: 27.05.1997 JP 154390/97



(71) Applicant: Kaneka Corporation
Osaka 530-8288 (JP)

(74) Representative:
Hubert, Philippe et al
Cabinet Beau de Loménie
158, rue de l'Université
75340 Paris Cédex 07 (FR)

(54) Cholesterol-lowering composition comprising coenzyme Q

(57) The present invention has its object to provide an antihypercholesterolemic or antihyperlipidemic agent, hence a therapeutic and prophylactic drug for arteriosclerosis, which is safer and more potent in cholesterol-lowering action than the hitherto-available drugs.

A cholesterol-lowering composition comprising a coenzyme Q of the following formula (I) or a reduced coenzyme Q of the following formula (II) as an active ingredient:





wherein n represents an integer of 6 to 11

EP 0 882 450 A2

Description

FIELD OF THE INVENTION

The present invention relates to a cholesterol-lowering composition comprising a coenzyme Q of the following formula (I) or a reduced coenzyme Q of the following formula (II) as an active ingredient.



In the formula n represents an integer of 6 to 11

More particularly, the present invention relates to use of a cholesterol-lowering composition comprising a coenzyme Q of the above formula (I) or a reduced coenzyme Q of the above formula (II) as an active ingredient in the therapy or prophylaxis of hypercholesterolemia, hyperlipidemia, and hence arteriosclerosis.

BACKGROUND ART

With the on-going advance in mean age of the population and changing dietary habit, the number of patients with arteriosclerosis and associated coronary or cerebral arterial disease is on the steady increase. While a number of etiologic factors has been suggested in the onset of arteriosclerosis, elevation of blood cholesterol is regarded as one of chief causative factors and it is being made increasingly clear that for the prevention and treatment of arteriosclerosis, a drug capable of lowering blood cholesterol is effective.

For the pharmacotherapy of hyperlipidemia, available in the main are blood cholesterol-lowering compositions comprising, as active ingredients, fibrates such as clofibrate, simfibrate, cinnofibrate, bezafibrate, etc.; nicotinic acid and its derivatives such as nicomol, niceritol, etc.; dextran sulfate; cholestyramine; probucol; 3-hydroxymethylglutaryl(HMG)CoA reductase inhibitors such as pravastatin, simvastatin, lovastatin, etc. [Mizushima, Y. & Miyamoto, A: "Konnichino-Chiryoyaku, Kaisetsu-to-Binran (Therapeutic Drugs Today, Comments and Guides) '97", pp. 419-426, Nankodo]. Among those blood cholesterol-lowering compositions, those comprising cholesterol biosynthesis inhibitors, namely HMG-CoA reductase inhibitors, are clinically highly valued because of their well-defined mechanisms of action and remarkable efficacy.

While those drugs are capable of lowering the blood concentration of cholesterol, they have risks for adverse reactions.

As side effects of fibrates, liver impairment, cholelithiasis, myositis, granuloblastosis, rhabdomyolysis, etc. have been reported.

As typical side effects of nicotinic acid derivatives, facial flush, rash, headache, and vomiting are known.

As side effects of HMG-CoA reductase inhibitors, liver impairment, rhabdomyolysis, elevation of creatine kinase (CPK), diarrhea, abdominal pain, etc. are known.

Even with cholestyramine and probucol, which are comparatively free from side effects, liver impairment and elevation of CPK are known to occur.

Hyperlipidemia in many cases is hyperlipidemia secondary to nephrotic syndrome, obstructive biliary tract disease,

hypothyrea, or diabetes and many of such patients have diseases other than hyperlipidemia as well. Thus, the recommended therapy for such patients begins with dietetic treatment and ergotherapy, followed by the above drug therapy depending on the time course of serum lipid. If any one drug fails to produce a sufficient response, a combined therapy using a plurality of drugs differing in the mechanism of action is carried out and favorable responses are then obtained in many cases. Thus, a plurality of drugs are used in patients with hyperlipidemia but the risk for drug interactions and potentiation of adverse reactions is increased. For example, the therapy using a fibrate and an HMG-CoA reductase inhibitor may induce rhabdomyolysis and associated acute renal failure.

Meanwhile, cholesterol biosynthesis starts with the synthesis of HMG-CoA from acetyl-CoA and acetoacetyl-CoA and reduction of the HMG-CoA by HMG-CoA reductase to mevalonic acid. Then, starting with mevalonic acid, synthesized are important physiological metabolites such as the cell membrane component sterol; heme A and coenzyme Q, which are involved in electron transport system; dolichol, which is necessary for glycoprotein synthesis; isopentyladenine for transfer RNA; various intracellular signal transporters; and steroid hormones. This process is known as the mevalonic acid pathway [J. L. Goldstein and M. S. Brown, *Nature*, **343**, pp.425-430, 1990].

Since HMG-CoA reductase mentioned above is a rate-determining enzyme involved in a comparatively early stage of cholesterol biosynthesis, any HMG-CoA reductase inhibitors can be utilized as a cholesterol-lowering agent. However, HMG-CoA reductase inhibitors represented by lovastatin inhibit synthesis of coenzyme Q at the same time [E. L. Appelkvist et al., *Clinical Investigator*, **71**, pp. S97-S102, 1993] and the physiological coenzyme Q level is decreased as a consequence. As a possible cause, it is suspected that the mevalonic acid pathway is shared by coenzyme Q biosynthesis and cholesterol biosynthesis in common.

Japanese Kokai Publication Hei-2-233611 discloses a method comprising using coenzyme Q₁₀ in combination with an HMG-CoA reductase inhibitor in order to make up for the decrease in coenzyme Q₁₀ caused by an HMG-CoA reductase inhibitor.


A. M. Bargossi et al. report cases in which the combined use of an HMG-CoA reductase inhibitor and coenzyme Q₁₀ precluded the decline in coenzyme Q₁₀ [Molecular Aspects of Medicine, **15**, pp. S187-S193, 1994]. Thus, while simvastatin monotherapy causes not only a fall in blood cholesterol but also a decrease in blood coenzyme Q₁₀, the combined therapy with simvastatin and coenzyme Q₁₀ may lead to a rise in blood coenzyme Q₁₀ without sacrificing the blood cholesterol-lowering effect of simvastatin. However, the dosage of coenzyme Q₁₀ in this combined therapy is the dosage required to make up for the decrease in coenzyme Q₁₀ without affecting the cholesterol-lowering action of the cardinal drug and is irrelevant to the effective dosage of coenzyme Q₁₀, i.e. use of coenzyme Q₁₀ as an independent active ingredient.

OBJECT AND SUMMARY OF THE INVENTION

In the view of the above state of the art, the object of the present invention is to provide an antihypercholesterolemic or antihyperlipidemic agent, hence a therapeutic and prophylactic drug for arteriosclerosis, which is safer and more potent in cholesterol-lowering action than the hitherto-available drugs.


After an extensive screening of compounds having cholesterol-lowering activity, the inventors found that a coenzyme Q of the following formula (I) and reduced coenzyme Q of the following formula (II) are highly capable of lowering the blood concentration of cholesterol and have developed the present invention on the basis of the above finding.

The present invention, therefore, is directed to a cholesterol-lowering composition comprising a coenzyme Q of the following formula (I) as an active ingredient:



wherein n represents an integer of 6 to 11

The present invention is also directed to a cholesterol-lowering composition comprising a coenzyme Q of the following formula (II) as an active ingredient:




wherein n represents an integer of 6 to 11

15 DETAILED DESCRIPTION OF THE INVENTION

The present invention is now described in detail.

The coenzyme Q of the above formula (I) is a class of physiological substances that are involved in electron transport in the mitochondria of living cells and ubiquitous in living things from microorganisms to higher animals.

20 The reduced coenzyme Q of the above formula (II) is readily transformed to the coenzyme Q of formula (I) in vivo, while this oxidized coenzyme Q is readily transformed to said reduced coenzyme Q in vivo. Therefore, the coenzyme Q in vivo can be generally expressed as follows:



35 wherein n represents an integer of 6 to 11

It is known that a substantial proportion of physiological coenzyme Q exists in the reduced form, the usual proportion being about 40 to 90%.

40 Because the coenzyme Q of formula (I) and reduced coenzyme Q of formula (II) have blood cholesterol-lowering activity, a cholesterol-lowering composition comprising said coenzyme Q of formula (I) or reduced coenzyme Q of formula (II) finds application as an antihypercholesterolemic agent, an antihyperlipidemic agent, and hence a therapeutic and prophylactic drug for arteriosclerosis.

Particularly, among species of said coenzyme Q of formula (I) and reduced coenzyme Q of formula (II), coenzyme Q₁₀ corresponding to n=10 and reduced coenzyme Q₁₀ corresponding to n=10 are coenzymes existing in higher animals inclusive of man and constitute one of the human body components. In human blood, it occurs in its lipoprotein fraction, with reduced coenzyme Q₁₀ accounting for no less than 80% of the coenzyme [Kishi, T., Mori, K. Japanese Society of Vitamins (ed.): Vitamin-no-Jiten (Dictionary of Vitamins), pp.402-413, Asakura Shoten]. Coenzyme Q₁₀ has heretofore been used as a therapeutic drug for congestive heart failure, a nutrient, or a nutritional supplement and has proved to be a safe substance. Therefore, it can be used with particular advantage as the active ingredient of the blood cholesterol-lowering composition of the invention.

The reduced coenzyme Q₁₀ can also be used with particular advantage as the active ingredient of the composition of the invention.

55 The above cholesterol-lowering composition can be safely administered orally or otherwise. The dosage form is not particularly restricted but can be freely selected from among powders, tablets, granules, capsules, injections, suppositories, and so on.

In preparing the above cholesterol-lowering composition, other pharmaceutically acceptable components may be mixed appropriately in conventional manners. Such components are not restricted in particular but includes an excipi-

ent, disintegrator, lubricant, binder, antioxidant, coloring agent, flocculation inhibitor, absorption promoter, solubilizer, stabilizer, etc.

The excipient mentioned above is not particularly restricted but includes sucrose, lactose, glucose, corn starch, mannitol, crystalline cellulose, calcium phosphate, and calcium sulfate, among others.

5 The disintegrator includes but is not limited to starch, agar, calcium citrate, calcium carbonate, sodium hydrogen-carbonate, dextrin, crystalline cellulose, carboxymethylcellulose, and gum tragacanth.

The lubricant includes but is not limited to talc, magnesium stearate, polyethylene glycol, silica, and hydrogenated vegetable oil.

10 The binder includes but is not limited to ethylcellulose, methylcellulose, hydroxypropylmethylcellulose, gum tragacanth, shellac, gelatin, gum arabic, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid, polymethacrylic acid, and sorbitol.

The antioxidant includes but is not limited to ascorbic acid, tocopherol, vitamin A, β -carotene, sodium hydrogen-sulfite, sodium thiosulfate, and sodium pyrosulfite.

15 The coloring agent is not particularly restricted but a suitable one can be selected from among the colors approved for use in pharmaceutical products.

The flocculation inhibitor includes but is not limited to stearic acid, talc, light silicic acid anhydride, and hydrous silicon dioxide.

The absorption promoter includes but is not limited to higher alcohols; higher fatty acids; and surfactants such as glycerin fatty acid esters.

20 The solubilizer includes but is not limited to organic acids such as fumaric acid succinic acid, and malic acid.

The stabilizer includes but is not limited to benzoic acid, sodium benzoate, and ethyl p-hydroxybenzoate.

The cholesterol-lowering composition of the present invention can be administered for the prevention or treatment of hypercholesterolemia or hyperlipidemia. Therefore, the cholesterol-lowering composition of the invention that is an antihypercholesterolemic or antihyperlipidemic agent is also an embodiment of the invention.

25 The dosage of the above cholesterol-lowering composition depends on the type and severity of hypercholesterolemia or hyperlipidemia but the usual dosage for an adult human is preferably about 100 mg to 10 g per day. Actually, the necessary efficacy is obtained at a higher dose compared with the dosage used in the combined therapy with an HMG-CoA reductase inhibitor.

30 The cholesterol-lowering composition of the present invention as described in detail above is a safe drug with a low risk for adverse reactions and can be used in the treatment and prevention of hypercholesterolemia, hyperlipidemia, and hence arteriosclerosis.

BEST MODE FOR CARRYING OUT THE INVENTION

35 The following examples and formulation examples illustrate the present invention in further detail, it being to be understood that those examples are by no means limitative of the scope of the invention.

Example 1 Cholesterol-lowering effect

40 Male ICR mice weighing about 20 g (5 individuals per group) were put on high cholesterol-cholic acid diet (71.9% standard ration, 15% sucrose, 2% sodium chloride, 10% coconut oil, 0.6% cholesterol, 0.2% cholic acid, 0.3% choline chloride) for feeding ad libitum from day 1 to day 7 of the experiment. On days 6 and 7, reduced coenzyme Q₁₀ was administered orally in doses of 150 mg/kg. As a positive control, the commercial antihyperlipidemic bezafibrate was administered orally in doses of 50 mg/kg. After the administration, the mice were deprived of food for 24 hours. On day

45 8, the blood was drawn from each animal and the serum was separated.

Heparin was added to an aliquot of the serum to cause precipitation and a heparin-precipitated lipoprotein fraction was recovered as low-density lipoprotein (LDL). The serum total cholesterol value and the cholesterol content in LDL were determined by the method described in the report of C. C. Allain et al. [Clinical Chemistry, 20, pp.470-475, 1974]. The % decreases in serum total cholesterol and LDL cholesterol were calculated by means of the following equation

50 (1), with the corresponding values in the negative control group being respectively taken as 100%.

$$\% \text{ Decrease} = \left(1 - \frac{\text{cholesterol in test group}}{\text{cholesterol in negative control group}} \right) \times 100 \quad (1)$$

55

The value found by subtracting LDL cholesterol from serum total cholesterol was calculated as high-density lipoprotein (HDL) cholesterol. The percent increase in HDL cholesterol was calculated by means of the following equation (2), with the corresponding value in the negative control group being taken as 100%.

$$\% \text{ Increase} = \left(\frac{\text{cholesterol in test group}}{\text{cholesterol in negative control group}} - 1 \right) \times 100 \quad (2)$$

The results are presented in Table 1. It can be seen from Table 1 that reduced coenzyme Q₁₀ has a definite property to lower total cholesterol in serum. It is particularly noteworthy that the drug causes a marked decrease in LDL cholesterol which includes cholesterol responsible for deposition of cholesterol on the vascular wall and consequent aggravation of arteriosclerosis and which is known as "risk-factor" cholesterol, and also a marked increase in HDL cholesterol which is said to prevent arteriosclerosis and is known as "antirisk-factor" cholesterol.

Comparison of the commercial antihyperlipidemic bezafibrate used as positive control with reduced coenzyme Q₁₀ revealed that although reduced coenzyme Q₁₀ was slightly inferior in the action to lower serum total cholesterol, it was somewhat superior in the property to lower LDL cholesterol and very prominent in HDL cholesterol-increasing activity. It is clear from the foregoing that reduced coenzyme Q₁₀ is a highly safe and superior cholesterol-lowering agent.

Table 1

	Negative control	Reduced coenzyme Q ₁₀	Bezafibrate
Serum total cholesterol (% decrease)	325±31 mg/dl (0%)	258±37 mg/dl (21%)	244±11 mg/dl (25%)
LDL cholesterol (% decrease)	245±33 mg/dl (0%)	160±39 mg/dl (35%)	171±16 mg/dl (30%)
HDL cholesterol (% increase)	80± 4 mg/dl (0%)	98± 4 mg/dl (23%)	73± 6 mg/dl (-9%)
Each cholesterol value (mg/dl) is mean ± S. E. (n=5)			

Formulation Example 1

Manufacture of Powders

Powders were manufactured using the following components. Coenzyme Q₁₀ was dissolved in acetone, adsorbed on microcrystalline cellulose, followed by drying. The mixture is mixed with corn starch to provide powders containing 20 mg of coenzyme Q₁₀ in each 200 mg.

Coenzyme Q ₁₀	10 parts by weight
Microcrystalline cellulose	40 parts by weight
Corn starch	50 parts by weight

Formulation Example 2

Manufacture of Tablets

Tablets were manufactured using the following components. Coenzyme Q₁₀ was dissolved in acetone, and adsorbed on microcrystalline cellulose, followed by drying. Then, corn starch, lactose, carboxymethylcellulose, and magnesium stearate were added and an aqueous solution of polyvinylpyrrolidone was further added as binder. The whole mixture was granulated in conventional manners and after addition of talc as lubricant, the granules were compressed to provide tablets containing 20 mg of coenzyme Q₁₀ in each tablet.

Coenzyme Q ₁₀	20 parts by weight
Microcrystalline cellulose	4 parts by weight
Corn starch	25 parts by weight

EP 0 882 450 A2

(continued)

Lactose	15 parts by weight
Carboxymethylcellulose	10 parts by weight
Magnesium stearate	3 parts by weight
Polyvinylpyrrolidone	5 parts by weight
Talc	10 parts by weight

Formulation Example 3

Manufacture of capsules

The following components were processed into granules in routine manners and dispensed into hard gelatin capsule shells to provide capsules containing 20 mg of coenzyme Q₁₀ per capsule.

Coenzyme Q ₁₀	20 parts by weight
Microcrystalline cellulose	40 parts by weight
Corn starch	20 parts by weight
Lactose	62 parts by weight
Magnesium stearate	2 parts by weight
Polyvinylpyrrolidone	3 parts by weight

Formulation Example 4

Manufacture of Soft Capsules

Soft capsules were manufactured using the following components. Soybean oil was heated to 60°C and coenzyme Q₁₀ melted at 60°C was added. To this mixture was added vitamin E in small portions and the resulting homogenate was encapsulated to provide soft capsules containing 20 mg of coenzyme Q₁₀ in each capsule.

Coenzyme Q ₁₀	20 parts by weight
Vitamin E	15 parts by weight
Soybean oil	350 parts by weight

Formulation Example 5

Manufacture of Powders

Using coenzyme Q₇ in lieu of coenzyme Q₁₀, the procedure of Formulation Example 2 was otherwise repeated to provide powders.

Formulation Example 6

Manufacture of Tablets

Using coenzyme Q₉ in lieu of coenzyme Q₁₀, the procedure of Formulation Example 3 was otherwise repeated to provide tablets.

Formulation Example 7

Manufacture of Capsules

- 5 Using reduced coenzyme Q₉ in lieu of coenzyme Q₁₀, the procedure of Formulation Example 4 was otherwise repeated to provide capsules.


Formulation Example 8

10 Manufacture of Soft Capsules

Using reduced coenzyme Q₁₀ in lieu of coenzyme Q₁₀, the procedure of Formulation Example 5 was otherwise repeated to provide soft capsules.

15 Claims


1. A cholesterol-lowering composition comprising a coenzyme Q of the following formula (I) as an active ingredient:



30 wherein n represents an integer of 6 to 11.


2. The cholesterol-lowering composition according to Claim 1 wherein the coenzyme Q is coenzyme Q₁₀, in which n is 10.

- 35 3. A cholesterol-lowering composition comprising a reduced coenzyme Q of the following formula (II) as an active ingredient:



50 wherein n represents an integer of 6 to 11.

4. The cholesterol-lowering composition according to Claim 3 wherein the reduced coenzyme Q is reduced coenzyme Q₁₀, in which n is 10.
5. The cholesterol-lowering composition according to Claim 1, 2, 3 or 4 which is a therapeutic and prophylactic drug
- 55 for hypercholesterolemia or hyperlipidemia.



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 882 450 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
03.11.1999 Bulletin 1999/44

(51) Int. Cl.⁶: **A61K 31/12**, **A61K 31/05**

(43) Date of publication A2:
09.12.1998 Bulletin 1998/50

(21) Application number: **98401263.3**

(22) Date of filing: **27.05.1998**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(72) Inventors:
• Mae, Tatsumasa
Kakogawa-shi, Hyogo 675-0102 (JP)
• Hidaka, Takayoshi
Kobe-shi, Hyogo 655-6006 (JP)

(30) Priority: **27.05.1997 JP 15439097**



(71) Applicant: **Kaneka Corporation**
Osaka 530-8288 (JP)

(74) Representative:
Hubert, Philippe et al
Cabinet Beau de Loménie
158, rue de l'Université
75340 Paris Cédex 07 (FR)

(54) **Cholesterol-lowering composition comprising coenzyme Q**

(57) The present invention has its object to provide an antihypercholesterolemic or antihyperlipidemic agent, hence a therapeutic and prophylactic drug for arteriosclerosis, which is safer and more potent in cholesterol-lowering action than the hitherto-available drugs.

A cholesterol-lowering composition comprising a coenzyme Q of the following formula (I) or a reduced coenzyme Q of the following formula (II) as an active ingredient:



wherein n represents an integer of 6 to 11

EP 0 882 450 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 98 40 1263

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	DIGIESI ET AL.: "Coenzyme Q10 in essential hypertension." MOLECULAR ASPECTS OF MEDICINE, vol. 15 Suppl, 1994, pages 257-263, XP002111735 * abstract * * page 259 * * page 262 *	1-3,5	A61K31/12 A61K31/05
X	SHINOTAWA ET AL.: "Protection against Adriamycin-induced toxicity in mice" ACTA MED. OKAYAMA UNIV. , vol. 41, no. 1, 1987, pages 11-17, XP002111736 Okayama, Japan * abstract * * page 12, right-hand column *	1-3,5	
X	EP 0 659 402 A (INDENA S.P.A.) 28 June 1995 (1995-06-28) * page 6; examples 3,4 * * claims 1,3 * * page 2, line 6,7 * * page 4, line 29,30 *	4	TECHNICAL FIELDS SEARCHED (Int.Cl.6) A61K
X	US 5 318 993 A (BRISTOL-MYERS SQUIBB COMPANY) 7 June 1994 (1994-06-07) * column 1, line 7,8 * * column 1, line 54-56 * * column 2, line 36-38 * * column 2, line 44,45 * * column 2, line 49-54 *	1-5	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 2 September 1999	Examiner Brunnauer, H
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03/92 (P04/C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 40 1263

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

02-09-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0659402 A	28-06-1995	IT 1265312 B	31-10-1996
		AU 677048 B	10-04-1997
		AU 6313294 A	13-07-1995
		CA 2123739 A	22-06-1995
		CN 1111506 A	15-11-1995
		DE 659402 T	10-10-1996
		ES 2081781 T	16-03-1996
		FI 942452 A	22-06-1995
		GR 96300007 T	29-02-1996
		JP 7196534 A	01-08-1995
		US 5648377 A	15-07-1997
US 5318993 A	07-06-1994	NONE	